Distúrbio do sistema imunológico que ocorre após o transplante alogênico de células-tronco hematopoiéticas e é uma reação das células imunológicas do doador contra os tecidos do hospedeiro. As células T do doador ativadas danificam as células epiteliais do hospedeiro após uma cascata inflamatória que começa com o regime preparativo.
Introdução
O que você precisa saber de cara
Distúrbio do sistema imunológico que ocorre após o transplante alogênico de células-tronco hematopoiéticas e é uma reação das células imunológicas do doador contra os tecidos do hospedeiro. As células T do doador ativadas danificam as células epiteliais do hospedeiro após uma cascata inflamatória que começa com o regime preparativo.
Tem tratamento?
Escala de raridade
<1/50kMuito rara
1/20kRara
1/10kPouco freq.
1/5kIncomum
1/2k
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Entender a doença
Do básico ao detalhe, leia no seu ritmo
Preparando trilha educativa...
Sinais e sintomas
O que aparece no corpo e com que frequência cada sintoma acontece
Partes do corpo afetadas
+ 28 sintomas em outras categorias
Características mais comuns
Os sintomas variam de pessoa para pessoa. Abaixo estão as 86 características clínicas mais associadas, ordenadas por frequência.
Linha do tempo da pesquisa
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Genética e causas
O que está alterado no DNA e como passa nas famílias
Nenhum gene associado encontrado
Os dados genéticos desta condição ainda estão sendo catalogados.
Diagnóstico
Os sinais que médicos procuram e os exames que confirmam
Tratamento e manejo
Remédios, cuidados de apoio e o que precisa acompanhar
Onde tratar no SUS
Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)
🇧🇷 Atendimento SUS — Doença do enxerto versus hospedeiro
Selecione um estado ou use sua localização para ver resultados.
Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.
Pesquisa ativa
Ensaios clínicos abertos e novidades científicas recentes
Ensaios em destaque
🟢 Recrutando agora
14 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.
Outros ensaios clínicos
1.644 ensaios clínicos encontrados, 21 ativos.
Publicações mais relevantes
Mostrando amostra de 200 publicações de um total de 13.788
Mesenchymal stromal cells as add-on therapy to anti-CD25 antibodies for treating gastrointestinal-involved steroid-refractory acute graft-versus-host disease: a multicenter, single-arm, pivotal clinical trial.
Steroid-refractory acute graft-versus-host disease (SR-aGVHD) is the predominant cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT), with gastrointestinal involvement (SR-GI-aGVHD) remaining a key obstacle. We conducted a multicenter, single-arm, pivotal trial to assess the efficacy and safety of hUC-MSC PLEB001, a human umbilical cord-derived mesenchymal stromal cells (MSCs) product, plus anti-CD25 monoclonal antibody as second-line therapy for SR-GI-aGVHD. Eligible patients with grade II or higher SR-GI-aGVHD received hUC-MSC PLEB001 with protocol-defined anti-CD25 monoclonal antibody therapy. hUC-MSC PLEB001 was infused at a dose of 106 cell/kg twice weekly for 4 consecutive weeks, starting at day 1, and efficacy was assessed on day 28. Patients achieving complete response (CR), progressive disease (PD) or no response (NR) concluded treatment; those with partial response (PR) continued the same regimen for additional 4 weeks. The primary endpoint of the study is the overall response rate (ORR) at day 28. Fifty-four patients (median age 43, range 14-68) were enrolled. The number of Grade II-IV SR-aGVHD patients was 21, 16, 17, respectively. Thirty-seven patients were GI-involved only, 15 patients were GI and skin involved, and 2 patients were GI and liver involved. The ORR at day 28 was 63.0% (95% CI 48.7%, 75.7%), with a CR rate of 55.6% (41.4%, 69.1%). The 28-day durable complete response rate (DCR) was 51.9% (37.8%, 65.7%). The ORR and CR rate at day 56 was 51.9% (37.8%, 65.7%) and 50.0% (36.1%, 63.9%), respectively. The overall survival (OS) for full analysis set (FAS) at day 28, 56, 100, 360 for the entire cohort were 94.4% (83.8%, 98.2%), 88.9% (76.9%, 94.9%), 79.6% (66.2%, 88.2%), 65.8% (51.1%, 77.0%) respectively. Treatment was well tolerated, and no infusion-related toxicity or treatment-related serious adverse events were observed. In this multicenter single-arm study, hUC-MSC PLEB001 plus anti-CD25 monoclonal antibody therapy was associated with clinically meaningful response rates and an acceptable safety profile in patients with SR-GI-aGVHD. These findings support further evaluation of MSC-based approaches within multimodal treatment algorithms for this challenging condition. Registry: Chinese Clinical Trial Registry, TRN: ChiCTR2300073965, Registration date: 2023-07-26 (retrospectively registered).
MHC class I on target cells regulates CD4+ T cell-mediated immunity.
Major histocompatibility complex (MHC) class I and class II molecules present antigens to CD8+ and CD4+ T cells respectively. Here we uncover a previously unrecognized role for MHC class I in modulating CD4+ T cell-mediated immunity. In allogeneic graft-versus-host disease and tumor models, we demonstrate that the absence of MHC class I on target cells significantly increases their susceptibility to CD4+ T cell cytotoxicity. Transcriptomic and functional studies suggest that this was because of heightened sensitivity to enhanced ferroptosis of the target cells. In large human transcriptomic and sequencing datasets, a role for CD4+ T cells in enhancing immune checkpoint blocker-mediated responses in persons with melanoma and mismatch-repair-deficient colon cancers that have downregulated MHC class I was suggested. These findings revise and expand the known role of MHC class I in CD8+ T cell and natural killer cell immunity and demonstrate a previously unrecognized role in CD4+ T cell-mediated cancer and alloimmunity.
Cognitive Functioning in Vorinostat-Treated Pediatric and Young Adult Patients Over the First 180 Days After Hematopoietic Stem Cell Transplant.
Cognitive and psychological difficulties could negatively interfere with treatment adherence and quality of life before and after hematopoietic stem cell transplant (HSCT). Methods to mitigate these changes may have positive effects on treatment success. Prior work has shown that histone deacetylases (HDAC) inhibitors such as vorinostat show promise in reducing the incidence of graft-versus-host disease (GVHD) in allogenic transplant recipients and may mitigate some of the cognitive changes seen following transplant in adults. The current work presents a planned secondary analysis of a phase I/II trial of vorinostat for GVHD prophylaxis (NCT03842696) to establish a cognitive and psychological safety profile for use of this emerging therapeutic in a sample of children, adolescents, and young adults. Thirty-two allogeneic transplant recipients (median age = 19) were evaluated with cognitive and health-related quality-of-life (HRQL) measures prior to transplant and at 100 days and 180 days after transplant (N = 25 (cognitive) and 25 (HRQL) at final endpoint). Kolmogorov-Smirnov tests and linear mixed effects modeling were used to compare cognitive performances and HRQL to normative levels and to examine changes over time. Notable cognitive impairments prior to transplant remained relatively stable throughout the first 180 days post-transplant, with no new neurocognitive safety signal over 180 days. Anxiety was apparent at baseline, but behavioral symptoms remained relatively well managed. Results highlight cognitive impairments present prior to transplant and support prior findings in an adult population, suggesting that vorinostat does not result in additional cognitive or psychological deficits following transplant.
GVHD prophylaxis with ATG and PTCy versus PTCy-based regimens in haploidentical stem cell transplantation: A CTTC study.
Graft-versus-host disease (GVHD) remains a barrier to long-term success of haploidentical donor (HID) allogeneic hematopoietic cell transplantation (HCT). Post-transplant cyclophosphamide (PTCy) is considered standard prophylaxis, while the addition of anti-thymocyte globulin (ATG) has been utilized by some centres to further reduce GVHD. We conducted a retrospective, multicenter analysis using the Cell Therapy Transplant Canada (CTTC) registry to compare outcomes of ATG-PTCy versus PTCy-only GVHD prophylaxis among adults undergoing HID HCT for hematologic malignancies between 2016-2023. Endpoints included overall survival (OS), acute GVHD (aGVHD), chronic GVHD (cGVHD), GVHD-free/relapse-free survival (GRFS), relapse, and non-relapse mortality (NRM). Multivariable Cox regression and propensity score matched analyses accounted for patient-, disease-, and transplant-related factors. 385 patients (148 ATG-PTCy, 237 PTCy) were included. Two-year OS and cumulative incidence of relapse (CIR) were similar between groups: 61% vs. 64% (p=0.29) and 19.6% vs. 19.4% (p=1.0). ATG-PTCy significantly reduced moderate-severe cGVHD: 11% vs. 30% (HR: 2.28, p=0.001), but two-year NRM was higher with ATG-PTCy: 27% vs. 18% (p=0.04), likely related to increased infection risk. Propensity-score matched analysis revealed no difference in OS (p=0.46), but lower moderate-severe cGVHD rates (p=0.002), higher relapse (p=0.009) and similar NRM (p=0.62) with ATG-PTCy. In AML patients (n=196), relapse remained similar, but OS favored PTCy (OS at 2-year 71% vs. 50%, p<0.001) due to excess NRM with ATG-PTCy. Multivariable analyses confirmed age and comorbidity burden as predictors of worse OS, while prophylaxis regimen independently influenced cGVHD risk. In this registry analysis, ATG-PTCy significantly reduced the incidence of moderate-to-severe cGVHD compared with PTCy alone; however, this benefit was offset by higher risks of relapse and NRM, ultimately yielding similar survival between the two regimens. These findings highlight the need for individualized prophylaxis strategies balancing GVHD prevention with infection-related risks.
Nonmyeloablative pentostatin-cyclophosphamide preconditioning improves rates of engraftment in adults undergoing haploidentical HCT for sickle cell disease.
The morbidity and mortality of sickle cell disease (SCD) remain high. Novel nonmyeloablative haploidentical hematopoietic cell transplant (HCT) regimens are being proposed. This report compared the effect of adding an IV pentostatin and oral cyclophosphamide (PC) preconditioning to the nonmyeloablative NIH HCT platform of alemtuzumab and total body irradiation (TBI) in adults with severe SCD. Transplant outcomes were compared to a historical HCT cohort that did not receive the PC preconditioning. Thirty-nine adult SCD patients were included. The median age was 33 years, 61% were male, and 92% were HbSS genotype. The median follow-up was 6.5 years. Many patients had severe end-organ damage, including dialysis-dependent end-stage kidney disease (8%) and cirrhosis (10%). One-year overall survival was 95%. The PC regimen was associated with a reduction in acute rejection one-year post-HCT (5% vs. 44%; p = 0.004) and lower graft failure rates throughout the follow-up period. After a median follow-up of 5.2 years, the disease-free survival was 71% for the PC regimen. The PC preconditioning was associated with higher rates of full donor chimerism at 2-years post-HCT (0% vs. 43%; p = 0.02). Grade II-IV acute graft-versus-host disease (GVHD) rates were low; no patients developed moderate to severe chronic GVHD. There remain no cases of myeloid malignancy after PC. With the increased immunosuppression of PC, 23% of patients developed post-transplant lymphoproliferative disorder, 19% developed immune cytopenias, and 62% had viral reactivation. Further study to determine an optimal nonmyeloablative haploidentical regimen for SCD patients with compromised organ function is imperative. ClinicalTrials.gov (NCT00977691, NCT03077542).
Publicações recentes
CAR Treg therapies for neurodegenerative diseases.
Lung Biopsies in Patients Referred for Allogeneic Hematopoietic Cell Transplantation: Diagnostic Accuracy, Diagnostic Yield, and Clinical Utility.
[The influence of different collagenases on the analysis of immune cells in salivary glands of mice with chronic graft-versus-host disease].
It mite not be graft-versus-host disease: frequency and clinical features of Demodex folliculitis after allogeneic hematopoietic cell transplantation.
Impact of G-CSF on Donor TCR Clonal Diversity and T Cell Function During Donor HSC Mobilisation.
📚 EuropePMC10.842 artigos no totalmostrando 199
Mesenchymal stromal cells as add-on therapy to anti-CD25 antibodies for treating gastrointestinal-involved steroid-refractory acute graft-versus-host disease: a multicenter, single-arm, pivotal clinical trial.
Stem cell research & therapyMHC class I on target cells regulates CD4+ T cell-mediated immunity.
Nature immunologyRisk factors associated with chronic cutaneous graft-versus-host disease following hematopoietic stem cell transplantation: a pediatric cohort.
Anais brasileiros de dermatologiaSecond allogeneic transplants in children: twelve years of experience.
Biomedica : revista del Instituto Nacional de SaludReduced-dose anti-thymocyte globulin combined with post-transplant cyclophosphamide versus standard ATG for graft-versus-host disease prophylaxis in haploidentical hematopoietic stem cell transplantation: a focus on chronic GVHD reduction.
Leukemia & lymphomaCognitive Functioning in Vorinostat-Treated Pediatric and Young Adult Patients Over the First 180 Days After Hematopoietic Stem Cell Transplant.
Pediatric blood & cancerReal-world evaluation of belumosudil for chronic ocular graft-versus-host-disease: Efficacy and outcomes.
Bone marrow transplantationSerum vitamin d levels predict hospital-free days in outpatient allogeneic stem cell transplantation survivors: implications for long-term health outcomes.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerGVHD prophylaxis with ATG and PTCy versus PTCy-based regimens in haploidentical stem cell transplantation: A CTTC study.
Transplantation and cellular therapyNonmyeloablative pentostatin-cyclophosphamide preconditioning improves rates of engraftment in adults undergoing haploidentical HCT for sickle cell disease.
PloS oneLetter to Editor Regarding: "Serum Pyroptosis-Related Cytokines as Biomarkers for Diagnostic Assessment and Risk Stratification of Ocular Graft-versus-Host Disease: A Case-Control Study" [Letter].
Journal of inflammation researchSignificant clinical impact of immunosuppressive therapy termination after allogeneic haematopoietic stem cell transplantation.
British journal of haematologyImpact of Post-Transplant Cyclophosphamide on the Prognostic Value of HCT-CI.
Transplantation and cellular therapyCD4-CD8-T Cell Reconstitution Combined with Acute GVHD and CMV Infection: A Robust Predictor of Overall Survival and Non-Relapse Mortality After HSCT.
Immunological investigationsConcerns regarding glomerular disease in chronic graft versus host disease (cGVHD).
NefrologiaOral Squamous Cell Carcinoma Secondary to Chronic Graft-versus-host Disease: Report of Three Cases.
The Tokai journal of experimental and clinical medicineEfficacy and safety of a new cladribine-based conditioning regimen for allogeneic hematopoietic stem cell transplantation in children with relapsed or refractory acute myeloid leukemia.
Frontiers in medicineCase Report: Allogeneic hematopoietic stem cell transplantation in a patient with triple-allele expression at both HLA-B and HLA-C loci.
Frontiers in immunologyClinical Development Programme of the Innovative Mesenchymal Stromal Cell Product MSC-FFM/MC0518 for Steroid-Refractory Acute Graft-Versus-Host Disease: Design of 2 Randomised Controlled Trials in Adult and Paediatric Patients.
Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und ImmunhamatologieA PRSZT Registry Analysis of Prognostic Factors Influencing Survival and Relapse Rates After Second Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoblastic Leukemia.
Pediatric blood & cancerIntegrative transcriptomic and machine learning analysis identifies core immune genes and pathways driving graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Leukemia researchRadiotherapy and Immune System Interactions Historical Perspectives and Clinical Advancements.
Molecular carcinogenesisCord blood versus matched related donor transplantation in AML not in remission: role of pre-engraftment immune reactions.
International journal of hematologyAn evaluation of axatilimab for the treatment of chronic graft-versus-host disease.
Expert opinion on biological therapyQuantitative evaluation of T-cell repertoire restoration following hematopoietic stem cell transplantation in patients with and without graft versus host disease.
Frontiers in immunologyMultisystem Lomentospora prolificans progression on fosmanogepix despite in vitro activity: a call for expanding clinical research on novel antifungals.
ASM case reportsWho is at risk? Clinical features and a predictive model for 30-day mortality in hematologic patients with enterococcal bloodstream infection.
Frontiers in cellular and infection microbiologyThe effect of cladribine-containing conditioning regimen on the efficacy and safety of allogeneic hematopoietic stem cell transplantation for children with acute lymphoblastic leukemia.
Stem cell research & therapyA living therapeutic platform for localized in situ modulation of macrophage pyroptosis ameliorates GVHD while preserving GVL.
Journal of nanobiotechnologySuperior outcomes with the FABT regimen in haploidentical transplantation for aplastic anemia in patients under 40 years old: a single-center retrospective study.
Clinical and experimental medicinePost-transplant Cyclophosphamide Reduces Bronchiolitis Obliterans Syndrome Risk Through Chronic Graft-versus-Host Disease Prevention: A Multicenter Cohort Study.
ChestRandomized trial of GvHD Prophylaxis in Haploidentical PBSC Transplantation: ATG, PTCy, and Low-Dose Combination Therapy.
BloodDigital Surveillance After Allogeneic Hematopoietic Stem Cell Transplantation Guides Therapeutic Interventions to Reduce Non-Relapse Mortality.
European journal of haematologyEvaluation of cyclophosphamide for steroid-refractory hepatic acute graft-vs-host disease after allogeneic hematopoietic stem cell transplantation.
Frontiers in immunology[Research Progress on the Impact of Donor-Recipient Sex on Prognosis after Allogeneic Hematopoietic Stem Cell Transplantation --Review].
Zhongguo shi yan xue ye xue za zhi[Clinical Analysis of Allogeneic Hematopoietic Stem Cell Transplantation for Very Early-Onset Inflammatory Bowel Disease Caused by IL-10RA Mutation].
Zhongguo shi yan xue ye xue za zhiComparison of clinical outcomes between early and delayed allogeneic hematopoietic stem cell transplantation for severe aplastic anemia: a single-center retrospective study.
Annals of hematologySymptom distress evolution over the first year after allogeneic stem cell transplantation - a prospective observational sub-study of the SMILe project.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerValemetostat Therapy for Relapsed Adult T-Cell Leukemia/Lymphoma After Allogeneic Hematopoietic Stem Cell Transplantation.
Hematological oncologyCord blood transfusion added matched unrelated donor transplantation as a preferable choice for aplastic anaemia: a comparative study from a single centre.
Annals of medicine[Mechanisms and clinical research progress of mesenchymal stromal cell therapy for steroid-refractory acute graft-versus-host disease].
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi[Efficacy and safety of basiliximab in gastrointestinal chronic graft-versus-host disease].
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFerritin as a pre-transplant biomarker for post-transplant outcomes in allogeneic stem cell transplantation using post-transplant cyclophosphamide.
Transplantation and cellular therapyGeneration and preclinical characterization of a novel bispecific CD19-TCRgammadelta antibody for the treatment of B cell acute lymphoblastic leukemia.
Frontiers in immunologyMicrotransplantation improves the outcome of older patients with newly diagnosed acute myeloid leukemia: a single-center study with long-term follow-up.
Frontiers in oncologyChronic graft versus host disease in upper limb: Calling upper limb rehabilitation specialists for improving outcomes in patients.
Clinical hematology internationalIn vivo stimulation of natural killer T cells and downstream regulatory T cells to reduce acute graft-versus-host disease.
Annals of translational medicineSuccessful Treatment of Primary Poor Graft Function After Haploidentical Hematopoietic Stem Cell Transplantation With Low-Dose Decitabine Followed by Donor Lymphocyte Infusion and Eltrombopag.
Cancer medicineBeyond HLA: An adaptive nanopore sequencing assay for simultaneous HLA and blood group profiling in transplantation.
Human immunologyTissue-Based Transcriptomic Profiling of Gastrointestinal Graft Versus Host Disease Reveals Immune and MicroRNA Dysregulation.
International journal of molecular sciencesEarly Marrow Microenvironment Immune Patterns After Hematopoietic Stem Cell Transplant in Pediatric Acute Lymphoblastic Leukemia Are Associated with Later Development of Chronic GvHD and Relapse.
International journal of molecular sciencesMetataxonomic Analysis and Fatty Acid Profiling of Feces from Children Undergoing Hematopoietic Stem Cell Transplantation.
International journal of molecular sciencesTIGIT Blockade Potentiates the Anti-Leukemic Activity of Exercise-Mobilized Donor Lymphocytes and Expanded γδ T-Cells.
CancersReal-World Outcomes of Ruxolitinib as Salvage Therapy in Steroid-Refractory Acute and Chronic Graft-Versus-Host Disease: A Multicenter Retrospective Observational Study from Turkey.
Journal of clinical medicineCurrent Diagnosis and Management of Ocular Graft-Versus-Host Disease at a Tertiary Cancer Center.
Journal of clinical medicineOverconsumption of fructose aggravates acute GVHD by inducing gut dysbiosis and promoting macrophage-mediated inflammatory response.
Gut microbesOutcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Pregnancy-Associated Aplastic Anemia.
Acta haematologicaImpact of nutritional source modality on weight loss and BMI reduction after hematopoietic stem cell transplantation.
Frontiers in oncologyOutcomes of hematopoietic stem cell transplantation for pediatric patients with transfusion-dependent thalassemia in Thailand.
Clinical and experimental pediatricsAllogeneic Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide in Patients With Large Paroxysmal Nocturnal Hemoglobinuria Clones.
European journal of haematologyPleuroparenchymal Fibroelastosis Complicated by Pulmonary Alveolar Proteinosis After Peripheral Blood Stem Cell Transplantation.
Respirology case reportsClinical Outcomes of Allogeneic Stem Cell Transplantation in Myelofibrosis - A Single Center Experience.
Blood cell therapyReal-World Outcomes of Allogeneic Stem Cell Transplantation in Relapsed Hodgkin Lymphoma: A Single-Center Experience from India.
Blood cell therapyNeuromyelitis Optica Spectrum Disorder in a Pediatric Patient Following Haploidentical Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia.
Blood cell therapyFecal Calprotectin as a biomarker for early diagnosis and prediction of steroid response in Acute Gastrointestinal Graft versus Host Disease.
Blood cell therapyNarrative Review of Preparative Regimens Predictive of Mixed Chimerism After HLA-Mismatched Hematopoietic Stem Cell Transplantation: A Starting Point for Combined Solid Organ and Stem Cell Transplantation.
Transplantation proceedingsFrom Treg, FOXP3 to RBPJ: Linking basic science and clinical medicine.
Taiwanese journal of obstetrics & gynecologyHaematopoietic stem cell transplantation outcomes for teenage and young adult patients with acute leukaemia: A British Society of Blood and Marrow Transplantation and Cellular Therapy registry study.
British journal of haematologyCurrent role of ATG in GVHD prevention: optimizing post-transplantation outcomes through combination with PTCY.
Current opinion in immunologyExperimental JAK inhibitors: the current, present, and future in graft-versus-host disease management?
Expert opinion on investigational drugsCytokine Signatures Outperform Immune Subsets in Machine Learning Models for Predicting Acute Graft-Versus-Host Disease at Neutrophil Engraftment.
Journal of immunology researchRisk factors for acute kidney injury after hematopoietic stem cell transplantation in children: a single-center retrospective study.
PeerJRethinking Immune Checkpoint Inhibition in Cancer.
Scandinavian journal of immunologyReduced relapse in high risk acute myeloid leukemia and myelodysplastic neoplasms with permissive HLA-DPB1 mismatches and post-transplant cyclophosphamide.
LeukemiaTooth loss and oral health-related quality of life in a sub-cohort within the Chronic Graft-versus-Host Disease Consortium.
Transplantation and cellular therapyEndothelial activation and stress index (EASIX) score is a stronger predictor of survival after allogeneic hematopoietic stem cell transplantation than acute-phase biomarkers.
CytotherapyImmune-mediated side effects of cancer immunotherapies.
BloodDe novo and quiescent cGVHD are distinguishable in a prognostic biomarker panel.
Frontiers in immunologyLetter to Editor Regarding: "Serum Pyroptosis-Related Cytokines as Biomarkers for Diagnostic Assessment and Risk Stratification of Ocular Graft-Versus-Host Disease: A Case-Control Study." [Response to Letter].
Journal of inflammation researchEvaluation of the Real-World Efficacy of Hetrombopag for the Treatment of Thrombocytopenia Postallogeneic Hematopoietic Stem Cell Transplantation.
Transplantation and cellular therapyEfficacy and safety of ruxolitinib for graft-versus-host disease prophylaxis in patients with aplastic anemia undergoing PBSC-only allogeneic stem cell transplantation: a prospective phase II study.
Experimental hematology & oncologyChronic graft-versus-host disease: Current situation and unmet needs - A European position statement.
Bone marrow transplantationEffect of vitamin D replacement on nutritional status and muscle strength in patients after allogeneic stem cell transplantation and chronic graft-versus-host disease.
Clinical nutrition ESPENSpanish real-world experience with belumosudil for chronic graft-versus-host disease after two or more prior lines of therapy.
Transplantation and cellular therapyRuxolitinib as a Steroid-Sparing Treatment for Chronic Graft-Versus-Host Disease.
Transplantation and cellular therapyThe prognostic impact of myeloid co-mutation burden in TP53-mutated AML/MDS after allogeneic stem cell transplantation: a multicenter retrospective analysis.
Annals of hematologyAnti-thymocyte globulin (ATG)- or alemtuzumab-based graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic hematopoietic cell transplantation (HCT) for patients 40 years and older with acute lymphoblastic leukemia in first complete remission: a study from the EBMT Acute Leukemia Working Party.
Bone marrow transplantationEarly fecal metabolomic profiling for predicting acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Scientific reports[Primary humoral immunodeficiencies associated with enteropathies: An update].
La Revue de medecine interneProphylactic Donor Lymphocyte Infusions in Pediatric Patients With High-Risk Hematological Malignancies.
European journal of haematologyNeurological sequelae of chronic graft-versus-host disease: clinical spectrum and management considerations.
Internal medicine journalThe efficacy and safety of MSCs in GVHD prevention and the treatment of SR-aGVHD: a systematic review and meta-analysis of randomized controlled trials.
Stem cell research & therapyNonmyeloablative Conditioning Combined with Anti-CD117 Antibody Briquilimab in Older Adults with High-Risk AML and MDS.
BloodImmune reconstruction after allogeneic hematopoietic stem cell transplantation: rules, mechanisms, and applications.
Annals of hematologyEffect of pretransplant spleen volume on the prognosis of acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation.
Frontiers in immunologyGriscelli Syndrome in Two Siblings with Silvery Hair: A Case Report.
JNMA; journal of the Nepal Medical AssociationHaploidentical Hematopoietic Stem Cell Transplantation With Anti-Thymocyte Globulin in the Treatment of Older Adults With Hematological Malignancy.
EJHaemCryopreservation of Hemopoietic Cells for Allotransplant: Altered Immune Cell Subsets and Clinical Implications.
American journal of hematologyA Transfusion-Transmitted Chronic Hepatitis E Virus Infection After Allogeneic Bone Marrow Transplantation with Viral Clearance Following Immunosuppression Tapering.
Internal medicine (Tokyo, Japan)[Venetoclax plus azacitidine as successful bridging therapy to second transplantation for post-transplant extramedullary relapse of acute myeloid leukemia].
[Rinsho ketsueki] The Japanese journal of clinical hematologySystemic Immunosuppressant Cessation/Tapering Linked to MGD Progression Post-HSCT.
American journal of ophthalmologyRefining Busulfan Exposure Enhances Pediatric ALL HSCT Outcomes: Insights from the International FORUM Study.
Blood advancesHemopoietic stem cell transplantation for infectious mononucleosis-related aplastic anemia.
Annals of hematologyAllogeneic B7-H3-targeted CAR-Vδ1T cell therapy in advanced solid tumors: A phase I study.
Clinical cancer research : an official journal of the American Association for Cancer ResearchClinical burden of dry eye disease in patients with ocular graft versus host disease.
Academia medicine and healthTransforming the treatment of Alpha-Thalassemia: a single-center retrospective study on hematopoietic stem cell transplantation in transfusion-dependent pediatric patients.
Annals of hematologyEvaluation of corneal epithelial thickness mapping via spectral-domain OCT in patients after allogeneic haematopoietic stem cell transplantation.
The British journal of ophthalmologyIL1B rs1143627 and IL17A rs8193036 in the risk of Acute Graft Versus Host Disease in pediatric HSCT.
Leukemia researchLymphocyte subset reconstitution and clinical outcomes following haploidentical hematopoietic stem cell transplantation.
British journal of cancerBET inhibition blunts antibody production and macrophage-mediated fibrosis to restore lung function in murine cGVHD.
BloodPost-transplant cyclophosphamide as graft-versus-host disease prophylaxis for matched related donor hematopoietic stem cell transplantation in acute leukemia: a systematic review and meta-analysis.
Hematology (Amsterdam, Netherlands)Percentage of CD56+ monocytes at neutrophil engraftment is associated with the incidence of acute graft-versus-host disease.
Annals of hematologyVaginal Lengthening Procedures for Noncongenital Indications.
International urogynecology journalBronchiolitis Obliterans Syndrome Following High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation in a Pediatric Patient With Neuroblastoma.
CureusAnti-thymocyte globulin-resistant CD4+ memory T cells contribute to haplo-fever after allogeneic hematopoietic stem cell transplantation.
Blood science (Baltimore, Md.)Management of CMV Pneumonia, DAH, and BOS Following HSCT in a Child with β-Thalassemia: A Case Report.
Journal of inflammation researchLow-dose ruxolitinib as first-line therapy for acute graft-versus-host disease (aGVHD) increases the risk of Epstein-Barr virus (EBV) reactivation but not posttransplant lymphoproliferative disease (PTLD).
Cancer pathogenesis and therapyReal-World Utilization Pattern and Outcomes of Letermovir in Adult Cytomegalovirus-Seropositive Allogeneic Hematopoietic Cell Transplant Recipients: An International Retrospective Study From the Infectious Diseases Working Party of EBMT.
Transplant infectious disease : an official journal of the Transplantation SocietyPost-transplant Cyclophosphamide (PTCy) for HLA-Matched Hematopoietic Stem Cell Transplant (HCT) in Pediatric and Young Adult Patients with Hematologic Malignancies.
Transplantation and cellular therapyAllogeneic hematopoietic cell transplantation for partial RAG deficiency in children and adults: Excellent outcomes with a reduced-intensity posttransplantation cyclophosphamide-based approach.
The Journal of allergy and clinical immunologyCorneal staining: Beyond the grade.
The ocular surfaceChronic graft-versus-host disease suppressing CD56brightPerforinneg regulatory-like NK cells inhibit CD4+ T cells via PD-1, LAG-3, and TRAIL.
CytotherapyUmbilical cord blood-derived natural killer cells as a viable and potent source for adoptive cell therapy.
CytotherapyCAR-NKT cell therapy for tumors: promise and progress.
Pathobiology : journal of immunopathology, molecular and cellular biologyA novel GMP-manufactured medicinal product candidate composed of NK and γδ T cells as adjunct immunotherapy for hematopoietic stem cell transplantation.
Cell transplantationEfficacy and safety of Venetoclax combined with Azacitidine in the treatment of relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation - a single-center retrospective study.
Current research in translational medicineVLA-4 Agonist Promotes Engraftment and Immune Reconstitution of Allogeneic Hematopoietic Stem Cells.
Blood advancesRegulatory-like FOXP3+Helios+ CD4+ T conventional cells correlate with T cell activation after Orca-T immunotherapy.
BloodA universal platform for simultaneous TCRα/β removal enables safer and more potent TCR therapies and autoimmune modeling.
bioRxiv : the preprint server for biologyDifferential effects of two common GVHD prophylaxis regimens on the gut microbiome: Results from the BMT CTN 1801 study.
bioRxiv : the preprint server for biologyOral Microbiota and Clinical Outcomes in Allogenic Hematopoietic Stem Cell Transplantation: A Systematic Review.
MicroorganismsEfficacy and Long-Term Remission Following Haploidentical HSCT for Therapy-Related Acute Myelomonocytic Leukemia with Plasmacytoid Dendritic Cells Post-FCR Therapy for CLL: A Case Report.
Journal of clinical medicinePersonalizing Nutritional Therapy in Pediatric Oncology: The Role of Gut Microbiome Profiling and Metabolomics in Mitigating Mucositis and Enhancing Immune Response to Chemotherapy.
Children (Basel, Switzerland)Secondary Neoplasm in Survivors of Childhood Hematological Malignancies-Systematic Review.
Children (Basel, Switzerland)Anti-thymocyte globulin as salvage therapy for steroid-refractory acute graft-versus-host disease after unrelated cord blood transplantation.
Chinese medical journalThe intestinal microbiota as a key modulator of acute graft-versus-host disease.
Nature reviews. CancerImproved early transplant outcomes with reduced-dose PTCy and low-dose ATG in matched unrelated donor allogeneic transplantation for acute myeloid leukaemia.
British journal of haematologyHow I Treat: Selection of Hematopoietic Cell Donors in the Era of Post-Transplant Cyclophosphamide.
BloodHuman serum influences functional plasticity and transcriptomic landscape of γδ T cells in vitro.
Frontiers in immunologyPharmacomicrobiomics in blood cancers: How the gut microbiome and its metabolites shape drug efficacy and toxicity.
Critical reviews in oncology/hematologyOptimizing Haploidentical Donor Selection for Pediatric Hematopoietic Cell Transplant.
Journal of clinical oncology : official journal of the American Society of Clinical OncologyA peptide immunomodulator activates MST1 to expand and stabilize murine and human regulatory T cells for immune tolerance.
Science translational medicineGlobal Panoramic analysis of clinical research in cell therapy: clinical trial landscape, marketed products, and regulatory trends.
Frontiers in pharmacologyStem-like memory-T maintenance and differentiation into tissue-resident T cells sustain chronic graft-versus-host disease in mice.
Nature communicationsA multi-center clinical trial of allogeneic hematopoietic stem cell transplantation in transfusion-dependent thalassemia.
Nature communicationsNovel FABT-Based Conditioning Regimen With Haploidentical Transplantation for Severe Aplastic Anemia: A Prospective, Single-Center, Phase II Clinical Trial.
Transplantation and cellular therapyA Pilot Clinical Trial of a Group Coping Intervention for English and Spanish Speakers with Chronic Graft-Versus-Host Disease.
Research squareImpact of prior solid tumor on outcomes of hematopoietic stem cell transplantation for hematologic malignancies: a propensity score-matched study.
Frontiers in immunologyCan Cord Blood Unit Selection Improve Outcomes After Single-Unit Unrelated Cord Blood Transplantation for Non-Remission Acute Myeloid Leukemia?
Transplantation and cellular therapyAssessment of CMV infection in allo-HSCT recipients undergoing LMV prophylaxis by using an implemented diagnostic protocol to identify active viral replication.
Antiviral researchNatural killer cell encapsulation in core-shell proteinic adhesive microcapsules for persistent and localized release of cytotoxic factors.
Colloids and surfaces. B, BiointerfacesImpact of ABO compatibility on outcomes after allogeneic hematopoietic cell transplantation (HCT): increased risk of acute GVHD with ABO bidirectional mismatch, independent of traditional and emerging GVHD prophylaxis strategies.
CytotherapyPlatelets as immune sensors: monitoring immune dynamics and diagnosing disease states across multiple disorders.
EBioMedicineAssociation between the prognostic nutritional index and early mortality of AML patients after allogeneic HSCT: a retrospective cohort analysis.
Frontiers in oncologyEfficacy of chimeric antigen receptor natural killer cells in treatment of ovarian cancer. A meta-analysis of pre-clinical studies.
Immunologic researchEffective treatment of acute graft-versus-host disease following liver transplantation using an integrated regimen centered on antithymocyte globulin: a single-center experience.
Frontiers in immunologyHidden Toll of CRE Colonization: Tripled Three-Year Mortality Risk and Increased Bloodstream Infection Burden After Allo-HSCT-A Propensity-Adjusted Study.
Infection and drug resistanceEffect of Early Administration of Anti-MRSA Drugs for Febrile Neutropenia in Allogeneic Hematopoietic Cell Transplantation.
EJHaemNeutrophil extracellular traps, endothelial injury and use of abatacept for graft versus host disease prophylaxis.
HaematologicaRuxolitinib in treatment-naive or corticosteroid-refractory pediatric patients with chronic graft-versus-host disease: final analysis of the phase 2 REACH5 trial.
HaematologicaReal-world outcomes in refractory chronic graft-versus-host disease: the Italian multicenter experience with belumosudil.
HaematologicaAvoidance of related donors in CAEBV with germline immune variants: long-termoutcome of matched unrelated donor HSCT - a case report.
Annals of hematologyThe gut microbiome in graft-versus-host disease: mechanisms of immune modulation and therapeutic approaches.
Gut microbesLongitudinal Study of Late Acute and Chronic Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation: A Long-Term Follow-up Study from the Chronic Graft-Versus-Host Disease Consortium.
Transplantation and cellular therapyInterleukin-15 and innate effector cells as predictors of outcome in allogeneic hematopoietic cell transplantation.
Frontiers in immunologyAdvancements and challenges in CAR-NK cell therapy for cancer treatment.
Trends in biotechnologyPreclinical evidence of anti-CD19 CAR-T cell in vitro and in vivo efficacy against CD19-expressing acute myeloid leukemia.
Current research in translational medicineExploring Strategies for a Digital Tool to Support Medication Adherence Among Adolescents and Young Adults Undergoing Hematopoietic Stem Cell Transplant and Their Care Partners: Qualitative Formative Study.
JMIR formative researchInhibition of ROCK2 impedes osteoclastogenesis through Src-Ca2+-NFATc1 signaling pathway and alleviates ovariectomy-induced bone loss.
International immunopharmacologyThe BIOPREVENT machine-learning algorithm predicts chronic graft-versus-host disease and mortality risk using posttransplant biomarkers.
The Journal of clinical investigationGastrointestinal-localized polymorphic post-transplant lymphoproliferative disorder following kidney transplantation after allogeneic hematopoietic stem cell transplantation: a rare case report.
Clinical journal of gastroenterologyOutcome of initial cord blood transplantation with FM80TBI as conditioning regimen for acute myeloid leukemia.
Annals of hematologyComparing two different doses of anti-thymocyte globulin in allogeneic hematopoietic stem cell transplantation for transfusion-dependent thalassemia: an open-label, randomized clinical trial.
Therapeutic advances in hematologyCase report: Different outcomes of two cases of relapsed/refractory T cell acute lymphoblastic leukemia treated with anti-CD7 chimeric antigen receptor T cells bridging to allogeneic hematopoietic stem cell transplantation: from curative promise to fatal risk.
Frontiers in oncologyCase Report: Extracorporeal photopheresis for cutaneous lupus erythematosus induces putatively atheroprotective B and T cell responses.
Frontiers in immunologyHigh-dose vitamin C supplementation in patients undergoing allogeneic hematopoietic stem cell transplantation: A pilot randomized, triple-blind, placebo-controlled trial.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerDevelopment and Clinical Application of a Simultaneous Liquid Chromatography-Tandem Mass Spectrometry Method for Patients with Graft-versus-Host Disease to Quantify the Plasma Concentrations of Ruxolitinib and Posaconazole.
Biological & pharmaceutical bulletinOutcomes of DPB1 Mismatch in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation: Time to Move Past Chromosome 6?
Transplantation and cellular therapyNatural killer and CAR-NK cell therapies in urological cancers: Progress, mechanistic lessons from CAR-T, and future directions.
Critical reviews in oncology/hematologyProposal for Diagnostic Criteria for Manifestations of Chronic Graft-versus-Host Disease in Peripheral Nervous System and Muscles.
Transplantation and cellular therapyComparison of nutritional risk index and body mass index in predicting survival outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective study.
Hematology, transfusion and cell therapyCell death pathways in graft-versus-host disease.
Current opinion in immunologyClinical analysis of fecal microbiota transplantation for refractory acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a five-year retrospective study.
CytotherapyInfection Complications in Pediatric Patients With Inborn Errors of Immunity After Umbilical Cord Blood Transplantation: A Chinese Single-Center Study.
Transplant infectious disease : an official journal of the Transplantation SocietyChronic graft-versus-host disease has similar or worse impact on skin-specific quality of life than autoimmune connective tissue diseases: A cross-sectional study.
Journal of the American Academy of DermatologyBrute force: the effects of ibrutinib on brexu-cel.
Blood advancesRecent advances in the pathophysiology of acute and chronic graft-versus-host disease.
International journal of hematologyModel-Informed Abatacept Dose Recommendation in Pediatric Patients With Acute Graft Versus Host Disease.
Journal of clinical pharmacologyOptimizing Autologous Serum Tear Therapy for Dry Eye Disease: Strategies and Innovations.
Journal of clinical medicineThe Effect of Post-Transplant Cyclophosphamide Administration on Graft-Versus-Host Disease in Allogeneic Bone Marrow Transplantation.
CancersComprehensive evaluation of taste dysfunction in allogeneic hematopoietic cell transplant recipients: a combined subjective and objective assessment.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerMetabolic reprogramming in lacrimal gland GVHD: Stage-specific shifts in acinar cells as drivers of disease progression.
The ocular surfaceSuccessful reduced-intensity cord blood transplantation in infants with familial hemophagocytic lymphohistiocytosis type 2.
International journal of hematologyTreosulfan/fludarabine versus thiotepa/busulfan/fludarabine for allogeneic haematopoietic cell transplantation in lymphoma in the post-transplant cyclophosphamide era: A GETH-TC study.
British journal of haematologyComparison of Total Leukocyte Chimerism and Lymphocyte Subset Chimerism for Early Detection of Post-Transplant Complications.
Transplant immunologyThreshold for cytomegalovirus DNA PCR for preemptive treatment after allogeneic stem cell transplantation.
International journal of hematologyDesensitization Therapy Using Sirolimus and Anti-CD20 Monoclonal Antibody Based Regimen In Haploidentical Transplant Recipients Positive for Donor-Specific Anti-HLA Antibodies.
Transplantation and cellular therapyEx vivo-expanded allogeneic Vδ2 T cells specifically reduce reservoirs of HIV-1 following latency reversal.
JCI insightAssociation of CYP2C19 Single Nucleotide Polymorphism With Hemorrhagic Cystitis After Pediatric Allogeneic Hematopoietic Stem Cell Transplantation.
Clinical transplantationAssociações
Organizações que acompanham esta doença — pra ter apoio e orientação
Ainda não temos associações cadastradas para Doença do enxerto versus hospedeiro.
É de uma associação que acompanha esta doença? Fale com a gente →
Comunidades
Grupos ativos de quem convive com esta doença aqui no Raras
Ainda não existe comunidade no Raras para Doença do enxerto versus hospedeiro
Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.
Tire suas dúvidas
Perguntas, dicas e experiências compartilhadas aqui na página
Participe da discussão
Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.
Fazer loginDoenças relacionadas
Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico
Referências e fontes
Bases de dados externas citadas neste artigo
Publicações científicas
Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.
- Mesenchymal stromal cells as add-on therapy to anti-CD25 antibodies for treating gastrointestinal-involved steroid-refractory acute graft-versus-host disease: a multicenter, single-arm, pivotal clinical trial.
- MHC class I on target cells regulates CD4+ T cell-mediated immunity.
- Cognitive Functioning in Vorinostat-Treated Pediatric and Young Adult Patients Over the First 180 Days After Hematopoietic Stem Cell Transplant.
- GVHD prophylaxis with ATG and PTCy versus PTCy-based regimens in haploidentical stem cell transplantation: A CTTC study.
- Nonmyeloablative pentostatin-cyclophosphamide preconditioning improves rates of engraftment in adults undergoing haploidentical HCT for sickle cell disease.
- CAR Treg therapies for neurodegenerative diseases.
- Lung Biopsies in Patients Referred for Allogeneic Hematopoietic Cell Transplantation: Diagnostic Accuracy, Diagnostic Yield, and Clinical Utility.
- [The influence of different collagenases on the analysis of immune cells in salivary glands of mice with chronic graft-versus-host disease].
- It mite not be graft-versus-host disease: frequency and clinical features of Demodex folliculitis after allogeneic hematopoietic cell transplantation.
- Impact of G-CSF on Donor TCR Clonal Diversity and T Cell Function During Donor HSC Mobilisation.
Bases de dados e fontes oficiais
Identificadores e referências canônicas usadas para montar este verbete.
- ORPHA:39812(Orphanet)
- MONDO:0013730(MONDO)
- GARD:16642(GARD (NIH))
- Busca completa no PubMed(PubMed)
- Artigo Wikipedia(Wikipedia)
- Q1194520(Wikidata)
Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.
Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar
